Pete Humphries; Marian M. Humphries; Lawrence C. S. Tam; G. Jane Farrar; Paul F. Kenna; Matthew Campbell; Anna-Soph Kiang Springer-Verlag New York Inc. (2012) Saatavuus: Tilaustuote Pehmeäkantinen kirja
Stephen Broadberry; Bruce M. S. Campbell; Alexander Klein; Mark Overton; Bas van Leeuwen Cambridge University Press (2015) Saatavuus: Tilaustuote Kovakantinen kirja
Stephen Broadberry; Bruce M. S. Campbell; Alexander Klein; Mark Overton; Bas van Leeuwen Cambridge University Press (2015) Saatavuus: Tilaustuote Pehmeäkantinen kirja
Wayne M. Becker; Lewis J. Kleinsmith; Jeff Hardin; William S. Klug; Michael R. Cummings; Neil A. Campbell; Jane B. Reece; Manuel (2006) Saatavuus: Loppuunmyyty Moniviestin
C. MacFie Campbell; H. S. Langfeld; W. M. McDougall; A. A. Roback; E. W. Taylor Taylor & Francis Ltd (2014) Saatavuus: Tilaustuote Pehmeäkantinen kirja
The hereditary retinopathy, retinitis pigmentosa (RP), which affects 1 in 3,500 people worldwide, is the most common cause of registered visual handicap among those of the working age in developed countries. RP is a highly variable disorder where patients may develop symptomatic visual loss in early childhood, while others may remain asymptomatic until mid-adulthood. Most cases of RP segregate in autosomal dominant, recessive or X-linked recessive modes, with approximately 41 genes being implicated in disease pathology to date (RetNet). The extensive genetic heterogeneity associated with autosomal dominant RP (adRP) is an undisputed hindrance to the development of genetically based therapeutics.
